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5-HT
 
1A
 
 agonists induce central cholinergic antinociception.
 
PHARMACOL BIOCHEM BEHAV 
 
57
 
(4) 835–841, 1997.—The antinociceptive effects of the 5-HT
 
1A
 
 agonists buspirone
[3 mg/kg intraperitoneally (IP)], gepirone (3–6 mg/kg IP), and 8-OH-DPAT [3–5 mg/kg IP; 1–3 
 
m
 
g per mouse intracere-
broventricularly (ICV)] were examined in mice by using the hot-plate (thermal stimulus) and abdominal constriction (chemi-
cal stimulus) tests. Buspirone, gepirone, and 8-OH-DPAT produced significant antinociception, which was prevented by at-
ropine (5 mg/kg IP), the ACh depletor hemicholinium-3 (1 
 
m
 
g per mouse ICV), and the 5-HT
 
1A
 
 antagonist NAN 190 (0.5 
 
m
 
g
per mouse ICV), but not by naloxone (1 mg/kg IP), the GABA
 
B
 
 antagonist CGP 35348 (100 mg/kg IP), and pertussis toxin
(0.25 
 
m
 
g per mouse ICV). NAN 190, which totally antagonized buspirone, gepirone, and 8-OH-DPAT antinociception, did
not modify the analgesic effect of morphine (5 mg/kg subcutaneously). In the antinociceptive dose range, none of the 5HT
 
1A
 
agonists impaired mouse performance evaluated by rota-rod and hole board tests. On the basis of these data, it can be postu-
lated that buspirone, gepirone, and 8-OH-DPAT exert an antinociceptive effect mediated by a central amplification of cho-
linergic transmission. © 1997 Elsevier Science Inc.
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THE nonbenzodiazepine anxiolytic drugs buspirone, gepirone,
and 8-OH-DPAT are agonists of the serotoninergic 5-HT
 
1A
 
receptors in the central nervous system. Serotonin 5-HT
 
1A
 
sites are localized predominantly on the axon terminals of se-
rotoninergic neurons. They function as autoreceptors (14),
and their stimulation leads to the disinhibition of the cholin-
ergic system that is tonically inhibited by tryptaminergic con-
trol (11). Bianchi  et al. (4) demonstrated that the full 5-HT
 
1A
 
agonist 8-OH-DPAT was able to increase ACh release from
the cerebral cortex of freely moving guinea pigs. Recent stud-
ies have shown that buspirone, given systemically, produces
antinociception in several pain tests in rats (12). Giordano
and Rogers (13) reported that buspirone-induced analgesia
may be a nonopioid, adrenally mediated co- and/or epi-phe-
nomenon to core hypothermia evoked by 5-HT
 
1A
 
 receptor ag-
onism. Recently, it was reported that sumatriptan, another
5-HT
 
1A
 
 agonist, was able to induce antinociception in mice
and rats through a cholinergic mechanism (3).
It has long been known that the direct and indirect activa-
tion of the cholinergic system produces analgesia in both ani-
mals (1,2,9,16–18,21,23,24) and humans (20). Because suma-
triptan is endowed with cholinergic antinociceptive properties
and 8-OH-DPAT enhances ACh release, the goals of the
present study were to explore whether other 5-HT
 
1A
 
 agonists,
such as gepirone and 8-OH-DPAT, were able to increase the
pain threshold in mice and then investigate whether a cholin-
ergic mechanism underlies 5-HT
 
1A
 
 antinociception. More-
over, we examined whether such antinociception is mediated
via G
 
i/o
 
 proteins.
 
METHODS
 
Animals
 
Male Swiss albino mice (23–30 g) from the Morini breed-
ing farm were used. Fifteen mice were housed per cage, and
the cages were placed in the experimental room 24 h before
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the test for acclimatization. The animals were kept at 23 
 
6
 
1
 
°
 
C with a 12 L:12 D cycle (lights on at 0700 h), with food and
water ad lib. Animals were randomly assigned to a control
(saline solution) or a treated group (5-HT
 
1A
 
 agonists). Both
groups received a pretreatment consisting of injection of sa-
line or one of the following antagonists: atropine, hemicholin-
ium-3 (HC-3), CGP-35348, or NAN 190. All the antagonists
were injected 15 min before treatment, with the exception of
HC-3 and CGP 35348, which were administered, respectively,
5 h and 5 min before treatment. For pertussis toxin (PTX) ex-
periments, mice were randomly assigned to a vehicle (water
solution containing 0.01 M sodium phosphate buffer, pH 7.0,
with 0.05 M sodium chloride) or a PTX group (0.25 
 
m
 
g per
mouse). Naive animals did not receive any pretreatment,
whereas vehicle and PTX groups received a single intracere-
broventricular (ICV) injection on day 0.
All animals used were drug-naive. At least six mice per
group were employed. Four different tests were performed by
using separate groups of animals. All experiments were car-
ried out according to the guidelines of the European Commu-
nity Council. Furthermore, the experimental protocol was ap-
proved by the Ethical Committee of the Department of
Pharmacology of Florence.
 
Hot Plate Test
 
The method adopted was described by O’Callaghan and
Holtzman (26). Mice were placed inside a stainless steel con-
tainer, thermostatically set at 52.5 
 
6
 
 0.1
 
°
 
C in a precision wa-
ter bath from CW Mechanical Workshop, Siena, Italy. Reac-
tion times (s) were measured with a stopwatch, and each
animal was tested before pretreatment (pretest) and 15, 30,
and 45 min after treatment. The endpoint used was the licking
of the fore or hind paws. Those mice scoring below 12 s or
over 18 s in the pretest were rejected. An arbitrary cutoff time
of 45 s was adopted, after which the animals were immedi-
ately removed from the hot plate. Following a single pretreat-
ment with vehicle or PTX, the antinociceptive effect of 5-HT
 
1A
 
agonists was tested 11 days later. PTX was injected 11 days
before the experiment because we had previously observed
that the analgesic effects of some drugs, such as baclofen,
were prevented by PTX only 11 days after administration (8).
Because the ADP ribosylation of G
 
i/o
 
 proteins produced by
PTX is irreversible, we waited 11 days after pretreatment be-
fore performing the hot plate test to rule out the possibility
that a lack of antagonism could be due to allowing too short a
time for obtaining the PTX-induced inactivation of G
 
i/o
 
 pro-
teins.
 
Abdominal Constriction Test
 
The test was performed in the mice according to Koster et
al. (22). Mice were injected intraperitoneally (IP) with a 0.6%
solution of acetic acid (10 ml kg
 
2
 
1
 
). The number of stretching
movements was counted for 10 min, starting 5 min after acetic
acid injection.
 
Rota-Rod Test
 
The apparatus consisted of a base platform and a rotating
rod, 3 cm in diameter and 30 cm long, with a nonslippery sur-
face. The rod was placed at a height of 15 cm above the base.
Six disks divided the rod into five equal sections; thus, up to
five mice could be simultaneously tested on the apparatus.
Rotation speed of the rod was 16 rpm. The integrity of motor
coordination was assessed on the basis of the number of falls
from the rod in 30 s, according to Vaught et al. (31). Perfor-
mance was measured before and 15, 30, and 45 min after
treatment.
 
Hole Board Test
 
The hole board test consists in a 40-cm-square plane with
16 flush-mounted cylindrical holes (diameter 3 cm) distrib-
uted 4 by 4 in an equidistant, gridlike manner. Mice were
placed one at a time on the center of the board and left to
move about freely for a period of 5 min. Two electric eyes,
crossing the plane from midpoint to midpoint of opposite
sides, thus dividing the plane into four equal quadrants, auto-
matically signaled the movement of the animals on the surface
of the plane. Miniature photoelectric cells in each of the 16
FIG. 1. Dose–response curves of buspirone (A), gepirone (B), and
8-OH-DPAT (C) after IP administration in the mouse hot plate test.
The number of mice ranged between 6 and 15, with the exception of
the saline-treated controls (n 5 25). Vertical lines represent SEM.
*p , 0.05 and **p , 0.01 vs. saline-treated mice.
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holes recorded exploration of the holes (head plunging activ-
ity) by the mice.
 
Drugs
 
The following drugs were used: gepirone, buspirone, 8-OH-
DPAT hydrobromide (2-dipropylamino-8-hydroxy-1,2,3,4-tetra-
hydronaphthalene), NAN 190 hydrobromide [1-(2-methox-
yphenyl)-4-[4-(2-phthalimido)butyl]piperazine], and PTX (all
from RBI); atropine sulphate (from Sigma); hemicholinium-3
hydrobromide (HC-3), CGP 35348 (3-aminopropyldietho-
xymethyl-phosphinic acid), and reserpine (all from Ciba-
Geigy); sodium chloride and glacial acetic acid (both from
Merck); and morphine (from U.S.L. 10/D, Florence). All
drugs, with the exception of PTX, were dissolved in isotonic
saline solution (0.9% NaCl) immediately before use. Drug
concentrations were prepared in such a way that the necessary
dose could be administered in a volume of 10 ml/kg by the
subcutaneous (SC) or IP route. Intracerebroventricular ad-
ministration was performed under ether anaesthesia using iso-
tonic saline as the solvent, according to the method described
for mice by Haley and McCormick (15). Substances were in-
jected in the necessary dose dissolved in 5 
 
m
 
l. To ascertain the
exact point into which the drugs were administered, some
mice were injected ICV with 5 
 
m
 
l of India ink (diluted 1:10)
and their brains were examined macroscopically after sectioning.
 
Statistical Analysis
 
Results are given as the mean 
 
6
 
 SEM; analysis of variance,
followed by Fisher’s PLSD procedure for post hoc compari-
son, was used to verify significance between two means. Prob-
ability (
 
p
 
) values of less than 0.05 were considered significant.
Data were analyzed by using StatView for the Macintosh
(1992).
 
RESULTS
 
Buspirone, gepirone, and 8-OH-DPAT induced a signifi-
cant increase in the pain threshold in the mouse hot plate
(Fig. 1; Table 1) and abdominal constriction (Fig. 2) tests. In
the mouse hot plate test, antinociception from buspirone (3 mg/
kg IP), gepirone (3–6 mg/kg IP), and 8-OH-DPAT (3–5 mg/kg IP)
reached a maximum after 15 min, persisted for up to 30 min,
and then diminished 45 min after injection (Fig. 1A–C). The
antinociceptive effect of 8-OH-DPAT was still present after
ICV injection in the range of doses of 0.5–3 
 
m
 
g per mouse, as
reported in Table 1. The dose–response curves of buspirone,
gepirone, and 8-OH-DPAT on the abdominal constriction
test are illustrated in Fig. 2. The abdominal constriction test
was performed 15 min after administration of buspirone,
gepirone, and 8-OH-DPAT (i.e., the time of the maximum ef-
fect of the analgesics). The doses of the above-mentioned
compounds effective in the abdominal constriction test were
the same as those that were effective in the hot-plate test, with
the exception of gepirone, which showed analgesic properties
only at 6 mg/kg IP (Fig. 2).
Figure 3 shows that buspirone, gepirone, and 8-OH-DPAT
antinociception was completely prevented by the antimusca-
rinic agent atropine (5 mg/kg IP), the choline uptake blocker
HC-3 (1 
 
m
 
g per mouse ICV), and the 5-HT
 
1A
 
 antagonist NAN
190 (0.5 
 
m
 
g per mouse ICV). The antagonists were all injected
15 min before the analgesic compounds, with the exception of
HC-3, which was administered 5 h before the analgesic test.
Conversely, no modification in buspirone, gepirone, or 8-OH-
DPAT antinociception was obtained by pretreating the mice
with the opioid antagonist naloxone (1 mg/kg IP), the GABA
 
B
 
antagonist CGP 35348 (100 mg/kg IP), or pertussis toxin
(0.25
 
m
 
g per mouse ICV), as shown in Table 2. Furthermore,
8-OH-DPAT antinociception was not prevented by pretreat-
ment with reserpine at a dose of 2 mg/kg IP injected twice (48 h
and 24 h) before the test in the mouse abdominal constriction
test (controls 
 
5
 
 31.1 
 
6 
 
2.0 s; 8-OH-DPAT 
 
5
 
 13.1 
 
6
 
 3.4 s;
8-OH-DPAT + reserpine 
 
5
 
 29.3
 
 6
 
 2.1 s). The doses of nalox-
FIG. 2. Dose–response curves of buspirone, gepirone, and 8-OH-
DPAT in the mouse acetic acid abdominal constriction test. Buspirone,
gepirone, and 8-OH-DPAT were administered IP 10 min before the
test. The dose of the analgesic compound administered is reported in
each column. The number of mice ranged between 6 and 16. Vertical
lines represent SEM. *p , 0.01 and **p , 0.001 vs. saline-treated
mice.
 
TABLE 1
 
DOSE–RESPONSE CURVE OF 8-OH-DPAT VIA ICV INJECTION
IN THE MOUSE HOT PLATE TEST
Treatment
(
 
m
 
g per mouse ICV)
Licking Latency (s)
Before
Treatment
After Treatment
1min 30 min 4min
 
Saline 13.9 
 
6
 
 0.6 15.0 
 
6
 
 0.5 14.9 
 
6
 
 0.7 14.0 
 
6
 
 0.5
8-OH-DPAT (0.1) 14.
 
6
 
 0.4 16.2 
 
6
 
 0.9 14.0 
 
6
 
 1.1 15.3 
 
6
 
 0.9
8-OH-DPAT (0.5) 13.9 
 
6
 
 0.7 20.2 
 
6
 
 1.0* 20.6 
 
6
 
 1.1* 17.0 
 
6
 
 1.0
8-OH-DPAT (1.0) 14.2 
 
6
 
 0.6 23.1 
 
6
 
 1.8** 21.4 
 
6
 
 1.3* 20.3 
 
6
 
 1.4*
8-OH-DPAT (3.0) 13.1 
 
6
 
 0.5 26.1 
 
6
 
 2.1** 23.4 
 
6
 
 1.9** 19.
 
6
 
 1.7*
The number of mice ranged between 8 and 10. *
 
p
 
 
 
,
 
 0.0and **
 
p
 
 
 
,
 
 0.01 vs.
saline-treated mice.
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one and CGP 35348 used were those able to completely an-
tagonize antinociception induced by, respectively, morphine
(5 mg/kg SC) and baclofen (4 mg/kg SC). Figure 4 illustrates
that doses of 0.1 mg/kg IP and 0.5 
 
m
 
g per mouse ICV of NAN
190 were needed to completely antagonize the antinocicep-
tion induced by the 5-HT
 
1A
 
 agonist 8-OH-DPAT (5 mg/kg IP)
but did not interfere in any way with morphine (5 mg/kg SC)
evoked analgesia.
Finally, it should be noted that buspirone, gepirone, and
8-OH-DPAT elicited their antinociceptive effects without
changing general behaviour or motor coordination as revealed
by the rota-rod test, wherein the above-mentioned drugs did
not increase the number of falls from the rotating rod (Table
3). Furthermore, buspirone, gepirone, and 8-OH-DPAT did
not produce any modification of spontaneous motility or in-
spection activity as revealed by the hole board test (Fig. 5).
 
DISCUSSION
 
The 5-HT
 
1A
 
 agonists buspirone (30), gepirone (30), and 8-OH-
DPAT (5) were able to induce dose-dependent antinocicep-
tion in mice. The increase of the pain threshold was detected
by using both thermal (hot plate test) and  chemical (abdomi-
nal constriction test) stimuli. Antinociceptive doses were de-
void of any other modification of animal behaviour; motor co-
ordination, evaluated by the rota-rod test, and spontaneous
motility and inspection time, evaluated by the hole board test,
were not modified by buspirone, gepirone, or 8-OH-DPAT
administration at analgesic doses. The 5-HT
 
1A
 
 antagonist NAN
190 (6) completely prevented buspirone, gepirone, and 8-OH-
DPAT analgesia, suggesting the involvement of this 5-HT re-
ceptor subtype in their antinociceptive mechanisms. This pre-
vention of antinociception by NAN 190 was obtained by both
peripheral (IP) and central (ICV) administration, providing
evidence that the site of analgesic action is located in the cen-
tral nervous system (CNS). This hypothesis was confirmed by
the fact that 8-OH-DPAT, when injected ICV, showed anti-
nociceptive properties, and the intensity of this effect is com-
parable to that obtained after IP administration.
The antinociception produced by the 5-HT
 
1A
 
 agonists was
found to be dependent on a cholinergic activation, because
FIG. 3. Antagonism by atropine (5 mg/kg IP), HC-3 (1 mg per
mouse ICV), and NAN 190 (0.5 mg per mouse ICV) of buspirone-,
gepirone-, and 8-OH-DPAT-induced antinociception in the mouse
hot plate test. Atropine and NAN 190 were injected 15 min before
analgesic treatment, and HC-3 was injected 5 h before analgesic
treatment. Licking latency values were recorded 15 min after buspirone,
gepirone, or 8-OH-DPAT administration. The number of mice
ranged between 8 and 12. Vertical lines represent SEM. *p , 0.01 vs.
saline/saline-treated mice.
FIG. 4. Dose–response curve of NAN 190 via IP and ICV administration for antinociception induced by 8-OH-DPAT (5 mg/kg IP) in the
mouse hot plate test. NAN 190 was injected 15 min before analgesic treatment. Licking latency values were recorded 15 min after 8-OH-DPAT
administration. Morphine (5 mg/kg SC) was used as the nonserotoninergic reference drug. The dose of NAN 190 administered is reported in
each column. The number of mice ranged between 6 and 18, with the exception of the saline/saline-treated group (n 5 31). Vertical lines
represent SEM. *p , 0.01 vs. saline/saline-treated mice.
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this analgesia was antagonized by the muscarinic antagonist
atropine and by the ACh depletor HC-3. The prevention of
buspirone, gepirone, and 8-OH-DPAT antinociception by
ICV administration of HC-3 further supports the hypothesis
that the analgesic site of action of these compounds is located
in the CNS; moreover, the HC-3 antagonism suggests that the
analgesic drugs investigated act through a presynaptic mecha-
nism, facilitating cholinergic transmission. In agreement with
this interpretation, antinociception induced by direct musca-
rinic agonists (e.g., McN-A-343) was not decreased after ICV
administration of HC-3 (2). Furthermore, it has been demon-
strated that 8-OH-DPAT, by activating serotonergic autore-
ceptors, is able to increase ACh release from the cerebral cortex
of freely moving guinea pigs (4). The prevention of buspirone,
gepirone, and 8-OH-DPAT antinociception produced by the
5-HT
 
1A
 
 antagonist NAN 190 suggests, moreover, that the cen-
tral serotoninergic system, through 5-HT
 
1A
 
 receptors, exerts
an excitatory tone on the cholinergic system. The activation of
the central cholinergic system is, therefore, fundamental for
buspirone, gepirone, and 8-OH-DPAT antinociception. A large
difference exists between the analgesia induced in animals by
buspirone, gepirone, and 8-OH-DPAT and that induced by
direct muscarinic agonists and cholinesterase inhibitors. In
fact, whereas 5-HT
 
1A
 
 agonists produce antinociception with-
out any visible side effect, the direct muscarinic agonists and
the cholinesterase inhibitors provoke, simultaneously with the
analgesic effect, a clear cholinergic symptomatology (tremors,
sialorrhoea, diarrhoea, lacrimation, etc.).
TABLE 2
 
LACK OF EFFECT OF NALOXONE, CGP 35348, AND PTX ON BUSPIRONE-,
GEPIRONE-, AND 8-OH-DPAT-INDUCED ANTINOCICEPTION IN THE
MOUSE HOT PLATE TEST
Pretreatment Treatment
Licking Latency (s)
Before
Treatment
After Treatment
15 min 30 min 45 min
 
Saline Saline 14.6 
 
6 
 
0.6 14.4 
 
6
 
 0.7 13.8 
 
6
 
 0.6 14.0 
 
6
 
 0.3
Buspirone 15.0 
 
6
 
 0.4 23.2 
 
6
 
 1.2** 24.2 
 
6
 
 0.8** 18.6 
 
6
 
 0.9
Gepirone 14.4 
 
6
 
 0.5 26.1 
 
6
 
 2.2** 20.1 
 
6
 
 0.9** 17.7 
 
6
 
 1.1
8-OH-DPAT 13.1 
 
6
 
 0.6 27.1 
 
6
 
 2.0** 22.4 
 
6
 
 1.1** 18.5 
 
6
 
 1.1*
Naloxone Saline 13.7 
 
6
 
 0.7 12.8 
 
6
 
 1.3 14.1 
 
6
 
 1.7 13.8 
 
6
 
 1.9
Buspirone 15.1 
 
6
 
 0.9 23.4 
 
6
 
 2.4** 21.3 6 1.8* 16.5 6 1.0
Gepirone 14.7 6 0.8 24.2 6 2.7** 18.1 6 1.4 17.9 6 1.4
8-OH-DPAT 13.2 6 0.7 27.5 6 1.8** 21.3 6 2.0 16.7 6 1.3
CGP 35348 Saline 13.8 6 0.7 14.0 6 0.7 14.4 6 0.8 14.8 6 0.7
Buspirone 14.0 6 1.0 27.4 6 2.1** 21.2 6 2.1** 18.3 6 1.6
Gepirone 14.3 6 1.2 28.4 6 1.9** 24.0 6 3.9** 22.0 6 1.5*
8-OH-DPAT 14.6 6 0.9 25.4 6 2.2** 18.3 6 2.4 14.3 6 1.9
PTX Saline 13.5 6 1.0 13.6 6 0.8 14.1 6 0.7 13.2 6 0.9
Buspirone 15.1 6 0.6 25.7 6 1.9** 23.4 6 2.9** 20.2 6 1.8*
Gepirone 17.3 6 0.7 23.2 6 3.0** 22.7 6 2.0** 20.5 6 1.0*
8-OH-DPAT 14.8 6 0.5 25.8 6 2.5** 23.2 6 1.2** 20.1 6 2.4*
Naloxone (1 mg/kg IP) and CGP 35348 (2.5 mg per mouse ICV) were injected 5 min before bus-
pirone (3 mg/kg IP), gepirone (6 mg/kg IP), or 8-OH-DPAT (5 mg/kg IP), whereas PTX (0.25 mg
per mouse ICV) was administered 11 days before the test. The number of mice ranged between 8
and 10, with the exception of the saline-treated group (n 5 43). *p , 0.05 and **p , 0.01 vs saline-
treated mice.
TABLE 3
LACK OF IMPAIRMENT OF PERFORMANCE BY BUSPIRONE,
GEPIRONE, AND 8-OH-DPAT ADMINISTRATION IN
THE MOUSE ROTA-ROD TEST
Number of Falls in 30 s
After Treatment
Treatment
(mg/kg IP) n
Before
Treatment 15 min 30 min 45 min
Saline 8 4.2 6 0.4 3.1 6 0.4 2.1 6 0.3 0.9 6 0.2
Buspirone (3) 8 3.9 6 0.4 3.7 6 0.5 3.3 6 0.7 2.5 6 0.7
Gepirone (6) 8 2.9 6 0.7 1.4 6 0.4 1.0 6 0.2 0.9 6 0.3
8-OH-DPAT (5) 8 3.9 6 0.3 2.8 6 0.3 1.3 6 0.3 0.8 6 0.2
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The involvement of the opioid and GABAergic systems in
the buspirone, gepirone, and 8-OH-DPAT analgesic mecha-
nism of action can be ruled out because naloxone, in agree-
ment with Giordano and Rogers (13), and the GABAB
blocker CGP 35348 did not modify the antinociception in-
duced by the three 5-HT1A agonists. The doses and adminis-
tration schedules of the above-mentioned drugs were ideal for
selectively and completely preventing antinociception in-
duced, respectively, by morphine (10) and the GABAB agonist
baclofen (25). Giordano and Roger (13) supposed that the an-
tinociceptive effect of buspirone in rats was related to 5-HT1A-
induced hypothermia through a nonopioid adrenally medi-
ated mechanism. In our experimental conditions, this hypoth-
esis was not confirmed. In fact, the three compounds exam-
ined, in the same range of doses, have been demonstrated to
be effective not only in a thermal test (hot plate), in which hy-
pothermia could lead to a  misinterpretation of the data, but
also in a chemical test (abdominal constriction), indicating that
5-HT1A-induced hypothermia and antinociception were not
related. The adrenergic hypothesis for the antinociception in-
duced by 5-HT1A agonists can be ruled out, because pertussis
toxin, which inactivates Gi/o proteins, at doses able to prevent
noradrenaline (19) and clonidine (28) antinociception, was not
effective in preventing buspirone, gepirone, or 8-OH-DPAT
analgesia. Moreover, pretreatment of mice with the monoam-
ine store depletor reserpine did not produce any antagonism
of the 5-HT1A agonists 8-OH-DPAT and sumatriptan (3). The
doses and administration schedule of reserpine were able to
prevent antinociception induced by the antidepressant drugs
clomipramine and amitriptyline (7). The lack of antagonism
by pretreatment with pertussis toxin further supports the hy-
pothesis of a cholinergic mechanism underlying buspirone-,
gepirone-, and 8-OH-DPAT-induced antinociception. In fact,
PTX pretreatment was able to prevent opioid (27), catechola-
minergic, GABAergic (19), histaminergic (8), and purinergic
(29) analgesia but not muscarinic antinociception (8).
In summary, these data indicate that the 5-HT1A agonists
buspirone, gepirone, and 8-OH-DPAT are endowed with cen-
tral antinociceptive properties by potentiating endogenous
cholinergic activity.
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FIG. 5. Effects of buspirone (3 mg/kg IP), gepirone (6 mg/kg IP),
and 8-OH-DPAT (5 mg/kg IP), in comparison with D-amphetamine
(1 mg/kg SC), in the mouse hole board test. Buspirone, gepirone, 8-OH-
DPAT, and D-amphetamine were injected 15 min before the test. The
number of mice ranged between 7 and 10. Vertical lines represent
SEM. *p , 0.01 vs. saline-treated mice.
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